Novel CYP2C9 promoter variants and assessment of their impact on gene expression

被引:22
作者
Kramer, Melissa A. [1 ,2 ,3 ]
Rettie, Allan E. [4 ]
Rieder, Mark J. [5 ]
Cabacungan, Erwin T. [1 ,3 ]
Hines, Ronald N. [1 ,2 ,3 ]
机构
[1] Med Coll Wisconsin, TBRC, CRI, Dept Pediat,CPPT, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA
[3] Childrens Hosp & Hlth Syst, Childrens Res Inst, Milwaukee, WI USA
[4] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
[5] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
关键词
D O I
10.1124/mol.107.044149
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are a considerable number of reports identifying and characterizing genetic variants within the CYP2C9 coding region. Much less is known about polymorphic promoter sequences that also might contribute to interindividual differences in CYP2C9 expression. To address this problem, approximately 10,000 base pairs of CYP2C9 upstream information were resequenced using 24 DNA samples from the Coriell Polymorphism Discovery Resource. Thirty-one single-nucleotide polymorphisms (SNPs) were identified; nine SNPs were novel, whereas 22 were reported previously. Using both sequencing and multiplex single-base extension, individual SNP frequencies were determined in 193 DNA samples obtained from unrelated, self-reported Hispanic Americans of Mexican descent, and they were compared with similar data obtained from a non-Latino white cohort. Significant interethnic differences were observed in several SNP frequencies, some of which seemed unique to the Hispanic population. Analysis using PHASE 2.1 inferred nine common (> 1%) variant haplotypes, two of which included the g.3608C > T (R144C) CYP2C9*2 and two the g. 42614A > C (I359L) CYP2C9*3 SNPs. Haplotype variants were introduced into a CYP2C9/luciferase reporter plasmid using site-directed mutagenesis, and the impact of the variants on promoter activity assessed by transient expression in HepG2 cells. Both constitutive and pregnane X receptor-mediated inducible activities were measured. Haplotypes 1B, 3A, and 3B each exhibited a 65% decrease in constitutive promoter activity relative to the reference haplotype. Haplotypes 1D and 3B exhibited a 50% decrease and a 40% increase in induced promoter activity, respectively. These data suggest that genetic variation within CYP2C9 regulatory sequences is likely to contribute to differences in CYP2C9 phenotype both within and among different populations.
引用
收藏
页码:1751 / 1760
页数:10
相关论文
共 40 条
[1]   A NEW ORPHAN MEMBER OF THE NUCLEAR HORMONE-RECEPTOR SUPERFAMILY THAT INTERACTS WITH A SUBSET OF RETINOIC ACID RESPONSE ELEMENTS [J].
BAES, M ;
GULICK, T ;
CHOI, HS ;
MARTINOLI, MG ;
SIMHA, D ;
MOORE, DD .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (03) :1544-1552
[2]   Discovery of new potentially defective alleles of human CYP2C9 [J].
Blaisdell, J ;
Jorge-Nebert, LF ;
Coulter, S ;
Ferguson, SS ;
Lee, SJ ;
Chanas, B ;
Xi, T ;
Mohrenweiser, H ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2004, 14 (08) :527-537
[3]   Strong bias the location of functional promoter polymorphisms [J].
Buckland, PR ;
Hoogendoorn, B ;
Coleman, SL ;
Guy, CA ;
Smith, SK ;
O'Donovan, MC .
HUMAN MUTATION, 2005, 26 (03) :214-223
[4]   The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4α to synergistically activate the human CYP2C9 promoter [J].
Chen, YP ;
Kissling, G ;
Negishi, M ;
Goldstein, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (03) :1125-1133
[5]   Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :495-501
[6]   Clinical pharmacokinetics and pharmacodynamics of celecoxib - A selective cyclo-oxygenase-2 inhibitor [J].
Davies, NM ;
McLachlan, AJ ;
Day, RO ;
Williams, KM .
CLINICAL PHARMACOKINETICS, 2000, 38 (03) :225-242
[7]   Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].
Dickmann, LJ ;
Rettie, AE ;
Kneller, MB ;
Kim, RB ;
Wood, AJJ ;
Stein, CM ;
Wilkinson, GR ;
Schwarz, UI .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387
[8]   Regulation of human CYP2C9 by the constitutive androstane receptor:: Discovery of a new distal binding site [J].
Ferguson, SS ;
Lecluyse, EL ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :737-746
[9]   Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin [J].
Gage, BF ;
Eby, C ;
Milligan, PE ;
Banet, GA ;
Duncan, JR ;
McLeod, HL .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :87-94
[10]  
Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242